141 related articles for article (PubMed ID: 10877499)
1. Can early failure with nevirapine be rescued with efavirenz?
Briones C; Soriano V; Dona C; Barreiro P; González-Lahoz J
J Acquir Immune Defic Syndr; 2000 May; 24(1):76-8. PubMed ID: 10877499
[No Abstract] [Full Text] [Related]
2. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
van Leth F; Lange JM
Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
[TBL] [Abstract][Full Text] [Related]
3. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
[TBL] [Abstract][Full Text] [Related]
4. HIV/AIDS news: comparable anti-HIV antiviral efficacy of Viramune and Efavirenz--the Lancet publishes first large-scale comparison study.
Meyer-Kleinmann J
Infection; 2004 Jun; 32(3):7. PubMed ID: 15230276
[No Abstract] [Full Text] [Related]
5. Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations.
González de Requena D; Gallego O; Corral A; Jiménez-Nácher I; Soriano V
AIDS; 2004 Oct; 18(15):2091-4. PubMed ID: 15577634
[TBL] [Abstract][Full Text] [Related]
6. Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine.
Lecossier D; Shulman NS; Morand-Joubert L; Shafer RW; Joly V; Zolopa AR; Clavel F; Hance AJ
J Acquir Immune Defic Syndr; 2005 Jan; 38(1):37-42. PubMed ID: 15608522
[TBL] [Abstract][Full Text] [Related]
7. Efavirenz: resistance and cross-resistance.
Clotet B
Int J Clin Pract Suppl; 1999 Jun; 103():21-5. PubMed ID: 10622039
[TBL] [Abstract][Full Text] [Related]
8. Non-nucleoside reverse transcriptase inhibitors--an overview.
Bell C; Matthews GV; Nelson MR
Int J STD AIDS; 2003 Feb; 14(2):71-7. PubMed ID: 12662384
[No Abstract] [Full Text] [Related]
9. Protease inhibitor-sparing regimens: new evidence strengthens position.
Moyle GJ
J Acquir Immune Defic Syndr; 2003 Jun; 33 Suppl 1():S17-25; quiz S26-8. PubMed ID: 12946062
[No Abstract] [Full Text] [Related]
10. The role of NNRTIs in antiretroviral combination therapy: an introduction.
Nelson M
Int J STD AIDS; 2001 Nov; 12 Suppl 4():1-2. PubMed ID: 11589821
[TBL] [Abstract][Full Text] [Related]
11. Comparison of NNRTIs in antiretroviral-experienced patients.
Maggiolo F
Int J STD AIDS; 2001 Nov; 12 Suppl 4():10-7. PubMed ID: 11589823
[No Abstract] [Full Text] [Related]
12. NNRTI hepatotoxicity: efavirenz versus nevirapine.
Pulido F; Torralba M
J HIV Ther; 2002 Nov; 7 Suppl 2():S3-16. PubMed ID: 12735215
[No Abstract] [Full Text] [Related]
13. Other issues: penetration into sanctuary sites, immune reconstitution and NNRTI sequencing.
Stellbrink HJ
Int J STD AIDS; 2001 Nov; 12 Suppl 4():25-32. PubMed ID: 11589825
[No Abstract] [Full Text] [Related]
14. In vitro anti-HIV-1 synergy between non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz.
Kollmann C; Tremblay C; Giguel F; Chou TC; Hirsch MS
Antivir Ther; 2001 Jun; 6(2):143-4. PubMed ID: 11491419
[No Abstract] [Full Text] [Related]
15. The tolerability of efavirenz after nevirapine-related adverse events.
Clarke S; Harrington P; Barry M; Mulcahy F
Clin Infect Dis; 2000 Sep; 31(3):806-7. PubMed ID: 11017835
[TBL] [Abstract][Full Text] [Related]
16. Comparison of NNRTIs in antiretroviral-naïve patients.
Arribas J
Int J STD AIDS; 2001 Nov; 12 Suppl 4():3-9. PubMed ID: 11589822
[No Abstract] [Full Text] [Related]
17. [Efavirenz--comprehensive status of studies].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():79-81. PubMed ID: 16385886
[No Abstract] [Full Text] [Related]
18. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
Martínez E; Arnaiz JA; Podzamczer D; Dalmau D; Ribera E; Domingo P; Knobel H; Riera M; Pedrol E; Force L; Llibre JM; Segura F; Richart C; Cortés C; Javaloyas M; Aranda M; Cruceta A; de Lazzari E; Gatell JM;
N Engl J Med; 2003 Sep; 349(11):1036-46. PubMed ID: 12968087
[TBL] [Abstract][Full Text] [Related]
19. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study.
Matthews GV; Sabin CA; Mandalia S; Lampe F; Phillips AN; Nelson MR; Bower M; Johnson MA; Gazzard BG
AIDS; 2002 Jan; 16(1):53-61. PubMed ID: 11741163
[TBL] [Abstract][Full Text] [Related]
20. Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir.
Ochoa de Echagüen A; Arnedo M; Xercavins M; Martinez E; Rosón B; Ribera E; Domingo P; González A; Riera M; Llibre JM; Gatell JM; Dalmau D;
AIDS; 2005 Sep; 19(13):1385-91. PubMed ID: 16103769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
